Novo Holdings picks up injectables CDMO in push for single-use manufacturing tech
For 25 years, Ritedose has been a CDMO that’s provided sterile, aseptic production of single-dose medication for more than 8 billion doses. Novo Holdings has taken notice, acquiring the Columbia, GA-based company from AGIC Capital and Humanwell.
“The investment in Ritedose is perfectly aligned with our deep expertise in pharma services. We see myriad opportunities to have an impact at Ritedose,” Novo’s head of principal investments Abhijeet Lele said in a statement. “We are also particularly excited to be at the vanguard of increasing vaccine availability through the use of blow-fill-seal injectable technology.”
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.